Progen Industries Limited Files F-3 Shelf Registration with Securities and Exchange Commission
SYDNEY, Australia, March 22 /PRNewswire-FirstCall/ -- Progen Industries Limited today filed an F-3 Shelf Registration with U.S Securities and Exchange Commission.
When effective, this registration statement will allow Progen to issue, from time to time, up to $60 million in any combination of its ordinary shares and warrants over the next two years in the U.S.
The terms, amounts and pricing of any future issue of securities will be determined and announced at the time of the offering.
Any offering of common stock covered by the registration statement will be made only by means of written prospectuses and prospectus supplements. The registration statement relating to the common stock has been filed with the Securities and Exchange Commission, but has not become effective. Common stock may not be sold and offers to buy may not be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell, nor the solicitation of an offer to buy, nor shall there be any sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
A copy of the F-3 Shelf Registration has been posted on Progen's website: http://www.progen.com.au/?page=infilings.html
About Progen:
Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.
Progen's three key areas of focus are: * Clinical Development -- via a focused clinical trial program involving its two compounds PI-88 and PI-166. * Drug Discovery -- projects focusing on the development of potent, selective inhibitors of carbohydrate-protein interactions, which are implicated in many disease processes. * Manufacturing Services -- PI-88 manufacturing development and supply for the clinical program and contract manufacturing services. Progen Information: Justus Homburg Chief Executive Officer Progen Industries Limited T: +61 7 3842 3333 E: justus.homburg@progen.com.au Linton Burns Chief Financial Officer Progen Industries T: +61 7 3842 3333 E: linton.burns@progen.com.au Media Relations Australia: Rebecca Piercy Buchan Consulting T: +61 2 9237 2800 / +61 422 916 422 E: rpiercy@bcg.com.au Investor Relations Australia: Rebecca Wilson Buchan Consulting T: +61 417 382 391 E: rwilson@bcg.com.au Media Relations USA: Robert D. Stanislaro Financial Dynamics T: +1 212-850-5657 E: robert.stanislaro@fd.com Investor Relations USA: Evan Smith Financial Dynamics T: +1 212-850-5606 E: Evan.smith@fd.com
Progen Industries LimitedCONTACT: Progen Information: Justus Homburg, Chief Executive Officer,justus.homburg@progen.com.au, or Linton Burns, Chief Financial Officer,+61-7- 3842-3333, linton.burns@progen.com.au, both of Progen IndustriesLimited, +61- 7-3842-3333; or Media Relations Australia: Rebecca Piercy ofBuchan Consulting, +61-2-9237-2800 or +61-422-916-422, rpiercy@bcg.com.au,or Investor Relations Australia: Rebecca Wilson of Buchan Consulting,+61-417- 382-391, rwilson@bcg.com.au; or Media Relations USA: Robert D.Stanislaro of Financial Dynamics, +1-212-850-5657,robert.stanislaro@fd.com, or Investor Relations USA: Evan Smith ofFinancial Dynamics, +1-212-850-5606, Evan.smith@fd.com